Capricor Therapeutics (CAPR) Receivables - Net (2015 - 2024)
Capricor Therapeutics (CAPR) recorded quarterly Receivables - Net of $10.0 million in Q4 2024, little changed quarter-over-quarter from $10.0 million in Q4 2023, and little changed on a YoY basis from $10.0 million in Q1 2024.
Capricor Therapeutics (CAPR) Receivables - Net (2015 - 2024) Analysis & Trends
Capricor Therapeutics' Receivables - Net history runs 3 years deep, the most recent figure standing at $10.0 million for Q4 2024.
- In Q4 2024, Receivables - Net changed 0.0% year-over-year to $10.0 million; the TTM figure through Dec 2024 stood at $10.0 million (changed 0.0% YoY), while the FY2024 annual figure was $10.0 million, changed 0.0% from the prior year.
- Receivables - Net was $10.0 million for Q4 2024 at Capricor Therapeutics, roughly flat from $10.0 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $10.0 million in Q4 2023 to a low of $10.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Capricor Therapeutics | 1.53 Bn | 1.26 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 10.00 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Dec 31, 2015 | 2.40 Mn |
| Dec 31, 2015 | 2.40 Mn |
| Sep 30, 2015 | 2.10 Mn |
| Sep 30, 2015 | 2.10 Mn |
| Jun 30, 2015 | 1.70 Mn |
| Jun 30, 2015 | 1.70 Mn |